Cadonilimab (AK104) 是一种人源化四价 IgG1 双特异性抗体，靶向 PD1/CTLA4。Cadonilimab 阻断 PD-1 和 CTLA-4 通路，从而缓解其相应的免疫抑制作用，逆转肿瘤特异性 T 细胞衰竭。Cadonilimab 显著下调 FC 介导的效应功能，包括抗体依赖性细胞介导的细胞毒性 (ADCC)、抗体依赖性细胞吞噬 (ADCP)、补体依赖性细胞毒性 (CDC)。Cadonilimab 可用于转移性宫颈癌，其他恶性肿瘤如胃癌、GEJ 腺癌、非小细胞肺癌 (NSCLC) 的研究。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

Anti-PD-1 & CTLA-4 Reference Antibody (cadonilimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-PD-1 & CTLA-4 Reference Antibody (cadonilimab) is 98.79%, determined by SEC-HPLC.

Cadonilimab bound to PD-1 protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Cadonilimab bound to in human PD-1 Protein-His, and the EC50 was 0.09436 nM.

Cadonilimab bound to CTLA4 protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Cadonilimab bound to in human CTLA4 Protein-His, and the EC50 was 0.06733 nM.

Cadonilimab bound to huCTLA4-CHO cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Cadonilimab bound to huCTLA4-CHO cells, and the EC50 was 27.870 nM.

Cadonnilimab bound to PD-1-Jukat cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ) , and test by flow cytometry. As shown in fig, Cadonnilimab bound to PD-1-Jukat cells, and the EC50 was 1.071 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.